<DOC>
	<DOCNO>NCT02564107</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , effect quality life oral ibandronate ( Bondronat ) participant breast cancer metastatic bone disease . The anticipated time study treatment 25 week , target sample size 50 individual .</brief_summary>
	<brief_title>A Study Ibandronate ( Bondronat ) Participants With Metastatic Bone Disease</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Females least 18 year age Breast cancer Bone metastases Use bisphosphonates within last 3 month Prior use gallium nitrate metastron Severely impaired renal function Hypocalcemia primary hyperparathyroidism Central nervous system ( CNS ) metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>